The world has taken great strides in the realms of science and technology. Diseases that were once a pain in the neck are now cured with effectiveness and precision.
Today, cancer cells can be targeted and destroyed without harming healthy cells, and infectious diseases are tackled head-on with better precision. This is the power of recombinant antibody production, a revolutionary technique that has transformed the medical field.
The story of recombinant antibody production starts with your immune system. For many years, scientists were fascinated by the intricacies of this system. And in the 19th century, Paul Ehrlich, a German physician, introduced the concept of magic bullets, which were highly specific agents that could target disease-causing agents without harming the cells.
Fast forward to the 20th century, and a breakthrough in molecular biology and genetic engineering paved the way for the development of recombinant DNA technology. The technique allowed scientists to manipulate genes and develop novel combinations of genetic material. This game changer in the medical field opened new possibilities for producing highly specific and customizable antibodies. In this piece, you will learn everything you need to know about recombinant antibody production.
What Is a Recombinant Antibody?
Recombinant antibodies or rAbs are synthetic antibodies that indicate mono-specific binding to a single epitope similar to a monoclonal antibody. However, Recombinant Antibody Production starts at the genomic level and is wholly in vitro. Scientists utilize techniques of molecular biology to design and introduce synthetic genes coding for the antibody of interest into cell lines.
The concept of recombinant antibodies has existed since 1984 when Neuberger and Morisson cloned gene hybridomas and modified them. They were the first to express chimeric antibodies, the first recombinant antibody version.
In recombinant DNA technology, the gene encoding for light and heavy chain immunoglobulin fragments are synthesized artificially or amplified or amplified from cells that produce antibodies and cloned into phage vectors. The vectors are consequently introduced into expression hosts like mammalian cells, yeast, or bacteria to produce the functional antibody.
Recombinant antibodies come in full-length immunoglobulins, single-chain fragment variables of monovalent antibody fragments, multimeric formats, and fragment-antigen binding. These different formats allow researchers to apply the most suitable form.
For instance, fragment antigen binding can be used in all research applications, including immunofluorescence, immunohistochemistry, flow cytometry, western blotting, as well as therapeutic applications.
The Making of Recombinant Antibodies
The production of recombinant antibodies can be carried out through various genetic recombinant approaches or engineering. These methods are also called display technologies, including mammalian cells, yeast, and phage display. Phage display is the most common technique – it is an in vitro technology used to display recombinant proteins on the surface of viruses that infect bacteria, otherwise known as filamentous bacteriophages like the M13.
The first step of making recombinant antibodies is generating a library of antibodies with large phages, each with a different gene. You will then screen these antibodies to determine their interaction with the subject of interest.
For overview purposes, an antibody gene library for light and heavy immunoglobulin fragments amplified from cells that produce antibodies or synthesize artificially is cloned into the right expression vector and displayed on filamentous bacteriophages’ surface as antibodies.
Heavy and light chain immunoglobulins are cloned into the M13 and utilized to infect Escherichia coli. Consequently, the bacteriophages express and display a big collection of combined light and heavy chain fragments. Every page has a VH and VL pairing; when you combine them, you get a whole set of antibody fragments.
Next, the focus antibody is immobilized on a solid surface before applying the library. In these scenarios, unbound phages and non-specific phages are taken out in the washing steps. In contrast, specific phages which are still bound to the antigen that was immobilized are retained. This results in a collection of highly reactive antibodies.
The chosen phages can then be amplified in new selection cycles and E.coli.
Finally, clones that are target specific are screened and amplified for target binding, and they are then validated by cell sorting, immunoblotting, or DNA sequencing. When the process concludes, you get DNA sequences of versatile and highly specific antibodies that are highly versatile derived from the phages. These sequences can be used for recombinant antibody production.
Who Offers Recombinant DNA Production?
Some specialists in recombinant antibody production offer the necessary capacities and knowledge for a fast and qualitative expression of antibodies. Companies outsource their manufacturing to such a specialist.
Researchers must identify the right antigen to attack to make a monoclonal antibody. Some of the determining factors for functional antibodies are:
- Immune response
- Effector functions
- Long-term efficacy
Also Read: 10 Surprising Facts About The Brain
Humans have taken leaps and bounds in the development of biology and science. Antibody production is one of the areas where the advancements have been notable. The benefits of recombinant antibodies are confirmed by the number of publications on the rise citing their use.
Recombinant technology is full of promises. The ability to scale production easily and the short development duration will allow experts to explain more intricate and complex biological questions. This will result in a better understanding of diseases and new therapeutic strategies.